Karl S. Peggs
Expertise in
5
conditions

Karl S. Peggs

Uclh
London, ENG, GB 
Expertise in
5
conditions
Uclh
London, ENG, GB 

Overview

Karl Peggs practices practicing medicine in London, United Kingdom.

Mr. Peggs is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Cytomegalic Inclusion Disease, Hodgkin Lymphoma, Cytomegalovirus Infection, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 145 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

UCLH
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19
Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CD19CAT-41BBZ CAR-T Cells
Study Phase: Phase 1
COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
Enrollment Status: Completed
Publish Date: April 28, 2023
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Fludarabine, CAR19 T-Cells
Study Phase: Phase 1
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
Adoptive Immunotherapy With CD25/71 Allodepleted Donor T Cells to Improve Immunity After Unrelated Donor Stem Cell Transplant
Adoptive Immunotherapy With CD25/71 Allodepleted Donor T Cells to Improve Immunity After Unrelated Donor Stem Cell Transplant
Enrollment Status: Completed
Publish Date: July 21, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy With CMV TCR-transduced Donor-derived T Cells for Recipients of Allogeneic Haematopoietic Stem Cell Transplantation
CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy With CMV TCR-transduced Donor-derived T Cells for Recipients of Allogeneic Haematopoietic Stem Cell Transplantation
Enrollment Status: Suspended
Publish Date: September 12, 2018
Intervention Type: Genetic
Study Phase: Phase 1
View 4 Less Clinical Trials

145 Total Publications

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".
Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".
Journal: Haematologica
Published: August 01, 2026

Frequently Asked Questions about Karl S. Peggs

Is Karl S. Peggs a top-rated expert for Cytomegalic Inclusion Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Karl S. Peggs is classified as an Advanced expert for Cytomegalic Inclusion Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Karl S. Peggs participate in research or clinical trials?

Yes. Karl S. Peggs has published 145 articles and abstracts on conditions like Cytomegalic Inclusion Disease. You can view a list of Karl S. Peggs's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Peggs's expertise for a condition
ConditionClose
      View All 25 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile